Jul 3 |
Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture
|
Jul 2 |
Viatris’ Mylan no longer subject of DOJ drug price-fixing probe
|
Jul 2 |
U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
|
Jun 26 |
Here's Why You May Invest in Theravance (TBPH) Stock Now
|
Jun 25 |
Viatris Named to TIME’s World’s Most Sustainable Companies 2024 List
|
Jun 14 |
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea
|
Jun 13 |
Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope
|
Jun 11 |
Viatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
|
Jun 7 |
Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024
|
Jun 6 |
Viatris Inc. (VTRS) Presents at Jefferies 2024 Global Healthcare Conference (Transcript)
|